Category: Press Release

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 16, 2018– AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the

Download PDF – IND acceptance triggers $2M milestone payment from CANbridge to AVEO – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 14, 2018– AVEO Oncology (Nasdaq: AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in esophageal squamous cell cancer (ESCC). Under

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 7, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “Our U.S. registration strategy remains a key focus for AVEO, with topline readout of the Phase 3 TIVO-3 study expected in the fourth quarter of this year,” said Michael Bailey, president and chief executive officer

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 19, 2018– AVEO Oncology (NASDAQ: AVEO) today issued the following statement regarding its recentlyrevised guidance on the timing of topline data from the TIVO-3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma. “The Company expects to report topline results from the TIVO-3 study in the fourth quarter

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 25, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution. “We believe that inclusion in the widely referenced Russell U.S. Indexes reflects the significant progress we

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 31, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conferencein New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 8, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2018 and provided a business update. “We continue to work toward reporting topline results from our Phase 3 TIVO-3 Study, which we now anticipate will occur in the third quarter of 2018. We are working closely with our contract

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 26, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following

Download PDF Results Published in the European Journal of Cancer CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 21, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA®) as second-line treatment in advanced renal cell carcinoma (aRCC), in the European Journal of Cancer. The publication, titled “Efficacy of Tivozanib Treatment after Sorafenib